Get to know our clinical trials
Clinical trial to evaluate the safety and preliminary efficacy of GEN1055 in monotherapy and as combination therapy in participants with malignant solid tumors
GEN1055 IS AN EXPERIMENTAL DRUG, WHICH MEANS THAT IT HAS NOT YET BEEN APPROVED TO TREAT MALIGNANT SOLID TUMORS. THE TRIAL HAS 2 PARTS: PART 1 (DOSE ESCALATION) IS THE BEGINNING OF THE TRIAL, WHERE THEY ARE GOING TO LOOK FOR THE SAFEST DOSE TO CONTINUE WITH, AND PART 2 (SCALE-UP) IS WHERE THEY SCALE UP THE TRIAL AND GIVE THAT DOSE TO MANY MORE PARTICIPANTS.
Technical Summary
- FIRST-IN-HUMAN, OPEN-LABEL, DOSE-ESCALATION, FIRST-IN-HUMAN CLINICAL TRIAL WITH EXPANSION COHORTS TO EVALUATE THE SAFETY AND PRELIMINARY EFFICACY OF GEN1055 IN MONOTHERAPY AND AS COMBINATION THERAPY IN PARTICIPANTS WITH MALIGNANT SOLID TUMORS
- Code EudraCT: 2023-507049-28-00
- Protocol number: GCT1055-01
- Promoter: Genmab A/S
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.